ExecutiveOrdersEO
EO 14292Executive OrderTrump 47 · R Quiet signal

Executive Order 14292

Improving the Safety and Security of Biological Research

This executive order halts federal funding for dangerous gain-of-function research conducted by foreign entities in countries of concern (particularly China) and suspends federally funded domestic gain-of-function research pending new oversight policies. It mandates revised frameworks for dual-use research oversight and nucleic acid synthesis screening, requires reporting mechanisms for transparency, and imposes strict enforcement terms including potential 5-year funding bans for violations.

Federal Register Open PDF 90 FR 19611

Impact dates

  1. Develop and implement strategy for non-federally funded research; submit legislative proposal for authority gaps

  2. Revise or replace 2024 dual-use research oversight policy

  3. Revise or replace Nucleic Acid Synthesis Screening Framework

Market exposure

Policy exposure mapping — not investment advice. Illustrative public companies are incomplete and not recommendations.

Sectors

PharmaTechnology & softwareOther industrial

Mechanisms

Ban / prohibitionProcurementLicensing

Role pressure

  • MixedDomestic producer — U.S. biotech and life-science firms face stricter oversight and compliance costs, but may benefit from reduced foreign competition and redirected federal funding
  • AdverseImporter — Foreign entities in countries of concern lose U.S. federal funding for gain-of-function and related life-science research
  • MixedEquipment supplier — Nucleic acid synthesis providers must implement comprehensive screening mechanisms, creating compliance burden but potential market differentiation for compliant firms
  • UncertainDownstream manufacturer — Synthetic nucleic acid procurement restrictions may affect supply chains for biologics, vaccines, and research materials depending on provider compliance requirements

Geographies

USCNOTHER

Illustrative public companies

Curated watchlist matches by sector/role — incomplete; not a recommendation.

MMM3MGOOGLAlphabetAAPLAppleCATCaterpillarLLYEli LillyFCXFreeport-McMoRanGEVGE VernovaHONHoneywellQQQInvesco QQQ TrustJNJJohnson & JohnsonMRKMerckMETAMeta PlatformsMSFTMicrosoftNVSNovartisNVDANVIDIAORCLOraclePFEPfizerSPYSPDR S&P 500 ETF

Confidence: medium · Policy alerts

Key directives

  • Immediately end federal funding of foreign dangerous gain-of-function research in countries of concern per 42 U.S.C. 6627(c)
  • Immediately end federal funding of other life-science research in inadequately overseen foreign countries that could threaten public health/safety/security
  • Suspend federally funded domestic dangerous gain-of-function research until completion of revised oversight policy
  • Within 120 days: revise/replace 2024 dual-use research oversight policy with strengthened enforcement, audits, transparency, and 4-year review cycle
  • Within 90 days: revise/replace Nucleic Acid Synthesis Screening Framework with comprehensive procurement screening requirements
  • Within 180 days: develop strategy to govern non-federally funded dangerous gain-of-function research and submit legislative proposal for authority gaps
  • Require reporting mechanism for publicly available information on covered research programs and awards
  • Mandate contractual enforcement terms including False Claims Act materiality, foreign research certification, institutional liability, and up to 5-year funding ineligibility

Who is ordered

Timeline

Immediate

  • federal funding ends for foreign gain-of-function research in countries of concern
  • suspension of federally funded domestic dangerous gain-of-function research pending section 4(a) policy
  • agency heads must report exceptions to suspensions to OSTP

Near term (90d)

  • OSTP must revise/replace Nucleic Acid Synthesis Screening Framework
  • agencies must ensure synthetic nucleic acid procurement through compliant providers

Long term

  • OSTP must revise/replace dual-use research oversight policy within 120 days
  • strategy for non-federally funded research due within 180 days
  • legislative proposal for authority gaps due within 180 days
  • policies reviewed every 4 years

Risks & tensions

  • Biden Administration explicitly blamed for insufficient oversight, creating partisan framing
  • Definition of 'countries of concern' left to agency discretion with China as only named example
  • Scope of 'other life-science research that could reasonably pose a threat' is vague and may create uncertainty for researchers
  • Non-federally funded research strategy may exceed existing regulatory authority, requiring uncertain congressional action
  • Public transparency mandate conflicts with national security and intellectual property protections, requiring case-by-case balancing
  • Immediate funding cuts to foreign research may disrupt ongoing collaborations and countermeasure development
  • Suspension of domestic research pending policy revision could delay pandemic preparedness research
Executive Order 14292: Improving the Safety and Security of Biological Research · Executive Orders